Skip to content

Study · Observational study · n = 40 · 2026

4 results

Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.

Mandour MO, Stears A, Van Der Klaauw A, Flanagan C, Gaff L, Jenkins C, Savage DB

The Journal of clinical endocrinology and metabolism1 Aug 2026

PMID41866320 (opens in a new tab)PMCIDPMC13466956 (opens in a new tab)DOI10.1210/clinem/dgag126 (opens in a new tab)PepBankPUB-41866320
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundLipodystrophy syndromes (LD) are a group of rare conditions characterized by the generalized or partial absence and/or dysfunction of adipocytes. Due to the lack of fat storage capacity, excess lipid accumulates in other tissues, leading to severe insulin resistance. At present, effective therapeutic options remain limited, with metreleptin currently the only specific licensed treatment. To this end, we evaluated the therapeutic impact of tirzepatide in people with partial lipodystrophy (PLD).MethodsThis was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.ResultsForty patients with PLD were included FPLD1 like = 26 (65%), FPLD2 = 4 (10%), FPLD3 = 7 (17.5%), FPLD7 = 1 (2.5%), APLD = 1 (2.5%), unclassified = 1 (2.5%). 87.5% (n = 35) were female with a median age of 47 years (IQR 39-59) and a median BMI of 31.5 kg/m2 (IQR 27.3 to 35.5). After a median 9.5 month follow-up (IQR 7 to 11), marked reductions were seen in body weight from 91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4; P < .0001), in HbA1c from 65 mmol/mol (IQR 54.5 to 85) to 52 mmol/mol (IQR 39 to 62; P < .0001) and in serum triglycerides from 2.80 mmol/L (IQR 1.6 to 3.7) to 1.83 mmol/L (IQR 1.0 to 2.9; P = .0005). Daily insulin requirements fell from 177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5; P = .0028).ConclusionIn patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycemic control, serum triglycerides, and daily insulin requirement. We recommend further prospective studies to support these findings and to evaluate its impact earlier in the course of the disorder.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In people with partial lipodystrophy, median body weight fell from 91.0 kg to 82.8 kg after tirzepatide.

    In plain wordsIn people with partial lipodystrophy, body weight fell after tirzepatide treatment, from 91.0 kg to 82.8 kg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change
    Study

    n = 40

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · median follow-up 9.5 monthsAs given in this study (human).

    Measurements

    median body weight, baseline
    91 kg
    partial lipodystrophy
    median body weight, follow-up
    82.8 kg
    partial lipodystrophy

    Source sentences

    Summary
    marked reductions were seen in body weight from 91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4; P < .0001)
    1 context sentence
    Summary · context
    This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.
  2. 02HumanObservational studyEfficacy outcome

    In people with partial lipodystrophy, median HbA1c fell from 65 to 52 mmol/mol after tirzepatide.

    In plain wordsIn people with partial lipodystrophy, blood sugar control improved after tirzepatide, with HbA1c falling from 65 to 52 mmol/mol.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · median follow-up 9.5 monthsAs given in this study (human).

    Measurements

    median HbA1c, baseline
    65 mmol/mol
    partial lipodystrophy
    median HbA1c, follow-up
    52 mmol/mol
    partial lipodystrophy

    Source sentences

    Summary
    in HbA1c from 65 mmol/mol (IQR 54.5 to 85) to 52 mmol/mol (IQR 39 to 62; P < .0001)
    1 context sentence
    Summary · context
    This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.
  3. 03HumanObservational studyEfficacy outcome

    In people with partial lipodystrophy, median serum triglycerides fell from 2.80 to 1.83 mmol/L after tirzepatide.

    In plain wordsIn people with partial lipodystrophy, blood triglycerides fell from 2.80 to 1.83 mmol/L after tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSerum triglycerides change
    Study

    n = 40

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · median follow-up 9.5 monthsAs given in this study (human).

    Measurements

    median triglycerides, baseline
    2.8 mmol/L
    partial lipodystrophy
    median triglycerides, follow-up
    1.83 mmol/L
    partial lipodystrophy

    Source sentences

    Summary
    in serum triglycerides from 2.80 mmol/L (IQR 1.6 to 3.7) to 1.83 mmol/L (IQR 1.0 to 2.9; P = .0005)
    1 context sentence
    Summary · context
    This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.
  4. 04HumanObservational studyEfficacy outcome

    In people with partial lipodystrophy, median daily insulin requirement fell from 177.5 IU to 58.0 IU after tirzepatide.

    In plain wordsIn people with partial lipodystrophy, daily insulin needs fell from 177.5 IU to 58.0 IU after tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDaily insulin requirement change
    Study

    n = 40

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · median follow-up 9.5 monthsAs given in this study (human).

    Measurements

    median daily insulin, baseline
    177.5 IU
    partial lipodystrophy
    median daily insulin, follow-up
    58 IU
    partial lipodystrophy

    Source sentences

    Summary
    Daily insulin requirements fell from 177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5; P = .0028).
    1 context sentence
    Summary · context
    This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.